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Relationships between physicians and their industry partners have ranged from spectacular collaborations that produce
extraordinary advances in patient care, such as endovascular aneurysm repair, to humiliating scandals such as extravagant
trips and bogus “consulting” agreements resulting in legal actions. It is the latter which have led many to call for the end
of all physician-industry relationships, and the former which mandate their preservation.
While these two examples are representative of extremes at each end of the spectrum of this issue, in reality the
majority of physician-industry relationships are far more complex, and the line between appropriate and inappropriate,
and ethical and unethical, is hard to draw. The benefits of our relationships with industry are many: partnering to develop
new therapies and technologies, educating and training physicians around new therapies and technologies, support of
continuing medical education (CME), fellowship training, and patient education. The pitfall and danger of this
relationship is that support from industry, be it a meal, a pen, an educational grant, or flattery, may unduly and
inappropriately influence physician decision making around a specific company’s product. While it is clear that free trips
are not within the realm of proper interaction, what about unrestricted educational grants to institutions, or support of
CME activities, professional society meetings, and new device training?
As a result of the intense scrutiny of relationships between physicians and industry recently, multiple diverse entities
(Association of American Medical Colleges, American Medical Association, Accreditation Council for Continuing
Medical Education, professional medical associations, academic medical centers, industry, and government) have
generated guidelines and policies with very different perspectives, reflective of their different missions. These policies
range from vague and lenient, with only basic limitation of the physician-industry relationship, to extremely rigid and
strict, with only minimal interaction and mission support permitted.
Given the many changes in oversight and expectations for the relationship between physicians and industry, it is
important for vascular surgeons to be aware of the background behind these modifications, the evidence that they are
needed, and the positions of the diverse organizations and institutions that have already defined their policies on this
issue. (J Vasc Surg 2011;54:26S-30S.)
o
m
m
a
n
o
i
i
p
r
5
F
p
o
p
t
e
g
e
i
c
m
t
gEVIDENCE FOR THE INFLUENCE OF
INDUSTRY ON PHYSICIAN BEHAVIOR
An important driving force behind the move to reform
attitudes and policies around physician-industry relation-
ships is the growing body of evidence that gifts and other
forms of industry support affect physician behavior. The
receipt of a gift or honorarium has been shown to change
the attitude of the physician toward the entity giving the
gift.1 The frequency of visits to a physician by industry
representatives has correlated with escalation in the physi-
cian’s prescribing that representative’s product,2 and the
frequency of these visits by industry representatives have
increased in recent years. In a review of studies published
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26Sver a 16-year period, Wazana identified that physicians
et with representatives from industry four times per
onth. A recent national survey evaluating the financial
ssociation of physicians and industry showed that this
umber is much greater among certain specialties than
thers. In this study, family practitioners (FP) met with
ndustry representatives 16 times per month, followed by
nternists at 10 times per month, and surgeons at four times
er month. They found cardiologists were twice as likely to
eceive payments for their services as FP, and surgeons were
7% less likely to receive payments for their services than
P. With regard to practice type and industry relations,
hysicians in group and solo practices had the highest rate
f receiving payments for services, followed closely by
hysicians in university practices.3,4 The increase in indus-
ry visits to physicians may reflect the increase in marketing
fforts by industry, with some reports estimating this bud-
et at $12 to $15 billion annually.5
The physician relationship with industry begins at an
arly stage of the physician’s career as a medical student
nteracting with residents and mentors at sponsored lun-
heons. As young residents with relatively low incomes,
any “free” items are given to them by industry represen-
atives. As Wazana noted, residents receive an average of six
ifts per year from industry. 3 In addition to the numerous
uncheons hosted by industry, these gifts to trainees can
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Volume 54, Number 18S Singh et al 27Srange from pens to expensive textbooks. Another common
gift is financial support for trainees to attend educational
meetings, both industry sponsored and otherwise. Schneider
et al studied cohorts of internal medicine residents during
their entire residency; one group received an intervention in
the form of an educational workshop on physician-industry
relations; the control group did not undergo this interven-
tion. The authors found that over this period of time
residents became more likely to find small gifts from indus-
try, such as meals and pens, appropriate, while over the
same time period they became less likely to find larger gifts,
such as tickets to sporting events and sponsored travel to
educational events, to be appropriate. Over time, there was
no difference in attitudes toward propriety of industry gifts
between the group that received the intervention and the
one that did not. The authors concluded that changing
perceptions around industry-physician relationships re-
quired more aggressive efforts than the educational work-
shop that was used in the study.6 Blumenthal et al also
noted that as physicians mature in their careers, their rela-
tionships with industry evolve; they are less likely to receive
meals and gifts, and more likely to receive honoraria,
grants, and even trips.7
The nature of this relationship has been shown to create
a bias on physicians’ practice patterns; however, despite
these findings, most physicians do not believe their percep-
tions and behaviors are actually altered by gift-giving from
industry.8,9 The impulse to reciprocate, even if unrecog-
nized by the physician, is felt to be responsible for this
effect. Orlowski et al demonstrated that an increase in
prescription of the relevant drug increases after physicians
are visited by sales representatives and/or attended industry
sponsored symposia.10 As vascular surgeons, we have be-
come increasingly dependent on device technology to treat
our patients using minimally invasive endovascular thera-
pies. In this regard, it is important to review the experience
of other specialties with technology dependence, such as
orthopedics. Over a 5-year period, the manufacturers re-
sponsible for 75% of hip and knee replacement hardware
paid physician consultants $800 million for 6500 “consult-
ing” agreements.11 It does not require extensive research to
understand that consulting fees of this magnitude can skew
the judgment of any physician. While the literature is
plentiful regarding the influence of industry support on
physician behavior, to date there have been no studies
demonstrating adverse patient outcomes due to physician
industry relationships.4
EXISTING ORGANIZATIONAL AND
INSTITUTIONAL POLICIES
As a result of the factors outlined above, a number of
diverse organizations and institutions, from academic med-
ical centers to the Office of the Inspector General to phar-
maceutical companies, have generated their own policies
around the issue of physician-industry relationships regard-
ing standards for health care professionals and industry
relationships. Several professional medical associations
(PMA), including the American Medical Association aouncil on Ethical and Judicial Affairs, academic medical
enters (AMC), the Association of American Medical Col-
eges (AAMC), the Office of the Inspector General, the
.S. Senate Special Committee on Aging, and industry
ave each set forth statements. However, no overarching
uidelines or policies have been uniformly adopted. Even
o, by September 2008, 25 public and private academic
ealth centers, as well as Veterans Health Administration
VHA), dramatically strengthened their conflict of interest
COI) policies. This section will review some of the current
tatements by governmental entities, organizations, and
ndustry.
The Department of Veterans Affairs has led the way in
stablishing policy for its providers and their business rela-
ionships with pharmaceutical industry representatives.
hrough a VHA directive (2003-060) published October
1, 2003, a system-wide policy was enacted. 12 The direc-
ive covers product review, medical education sponsorship,
he conduction of drug and product studies, and responses
o requests for procurement of specific products. Further-
ore, it limits the interactions between vendors and physi-
ians to “appointments only” in order to control industry
ccess to all medical care facilities and staff.
Even more stringent are actions taken through the
ffice of the Inspector General (OIG). The OIG, overseen
y Inspector General Daniel R. Levinson, for the Depart-
ent of Health and Human Services and the Department
f Justice, has contributed substantial resources toward the
nvestigation and prosecution of companies and individuals
ho violate federal antifraud statutes, including the false
laims act and anti-kickback statutes. The use of financial
ncentives by a company to a physician in order to encour-
ge the use of a particular product is considered illegal and
ubject to major fines. Examples of such prosecutions in-
lude several multi-million dollar judgments against ortho-
edic device manufacturers and orthopedic surgeons who
eceived kickbacks for using specific devices, and judgments
f up to $50,000 for individual physicians receiving sham
consulting arrangements.” The OIG reports directly to
ongress and has given testimony there on the device
ndustry, physician relationships, and conflicts of interest.
n February 2008, the U.S. Senate Special Committee on
ging held a hearing entitled “Surgeons for Sale? Conflicts
nd Consultant Payments in the Medical Device Indus-
ry.”13 The committee’s investigation found some of the
ayments to be excessive, illegitimate, and often improperly
ocumented.
The health system reform legislation signed into law in
arly 2010 includes a provision requiring pharmaceutical
nd device manufacturers to disclose physician payments,
ifts, honoraria, and travel of any amount. Several states,
ncluding Massachusetts, Minnesota, Vermont, Maine,
est Virginia, and the District of Columbia have similar
egislation ensuring transparency between physicians and
he companies with whom they interact, with Massachu-
etts adapting the most stringent regulations. At the same
ime, government is increasing its efforts to reduce fraud
nd impropriety; it recognizes the value of industry-
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September Supplement 201128S Singh et alphysician relationships in regard to the development and
testing of new medical therapies, technologies, and prod-
ucts and their importance in producing effective and safe
medications and devices.
In a related action, Senator Charles Grassley of Iowa
has begun investigating the relationship between industry
and professional medical associations. In December 2009,
Senator Grassley requested data on corporate support from
31 medical associations, including the American College of
Surgeons, the American Academy of Orthopedic Surgeons
(AAOS),14 the North American Spine Society, and many
others.
In June 2008, the AAMC published the results of a
special task force evaluating the impact of industry funding
of medical education and real or perceived conflicts of
interest between academia and industry.15 The report urges
academic medical centers to “accelerate their adoption of
policies” that regulate industry support and oversee con-
flicts of interest. The primary common recommendations
include: (1) prohibition of all on- and off-site gifts (includ-
ing meals); (2) prohibition of physician-, division-, or
department-directed pharmaceutical samples; (3) barring
acceptance of travel funds from industry except for legiti-
mate reimbursement for contracted services; (4) banning of
unrestricted industry representative access to faculty and
trainees; and (5) use of centrally-directed industry funds for
continuing medical education events. The AAMC also
recommends that education support from industry go
through a central distribution center within the academic
institution rather than to trainees, divisions, or depart-
ments. Though this type of procedure may be a form of
“money-laundering,” it directs funds to a central repository
to be used for educational pursuits and, thus, to be used in
an unrestricted fashion.
The Accreditation Council for Continuing Medical
Education (ACCME) has set six standards for commercial
support of continuing medical education (CME) events.16
The educational program and faculty must be designed and
determined in advance and independent of the sponsoring
organization(s); all providers and faculty must resolve their
personal COIs; commercial support must be used appro-
priately and independently of the sponsor(s); commercial
promotions must be done in appropriate locations, such as
exhibit halls, and must not be included in any educational
presentations or materials; the content and format of the
program must be free of commercial bias; and all providers
and faculty must fully disclose any COIs or potential COIs
in the program and prior to the beginning of their educa-
tional activity.
The third type of organizations discussing conflict of
interest and industry relationships are PMAs, such as the
Society for Vascular Surgery. Most PMAs receive a large
amount of funding from industry for educational meetings
and conferences. Most PMAs have guidelines for conflict of
interest and relationship disclosure; however, these guide-
lines are by no means uniform and often not very rigorous.
In addition, disclosure of conflict alone is no longer con-
sidered sufficient by newer standards – elimination of con- lict is now the goal. Physicians, patients, and governmental
nstitutes such as the Centers for Medicare and Medicaid, as
ell as law and policymakers, rely heavily on PMAs to guide
ealth care needs and provide evidence-based recommen-
ations. For this reason, PMAs are beginning to develop
tricter standards of behavior governing interaction be-
ween the PMA and industry, and individual members and
ndustry. The PMA–industry relationship is arguably the
ost complex and nuanced of all the interactions between
he medical profession and industry, as it encompasses so
any facets; individual physicians, CME, research, trainee
upport, training on new products and devices, and support
or the PMA itself.
The Council of Medical Specialty Societies (CMSS),
ith a membership of more than 30 national specialty
ocieties, developed guidelines for the interaction of pro-
essional medical associations with industry in November
009. The CMSS guidelines stress that the interactions
hould be for the benefit of patients and members and for
he improvement of care. CMSS recommended several
pecific ways that professional medical associations should
e more transparent about industry support and take ac-
ions to assure that association actions are not compro-
ised by conflicts of interest.
This is in contrast to the opinion of others who propose
more radical shift in attitude and policy around this issue.
othman et al published proposed guidelines for PMAs
ith regard to industry relations. In this article, the authors
ecognize the potential benefits of these relationships, but
rgue that industry goals and agendas (marketing and sales)
ust be separated from the PMAs’ goals (education and
mproving patient care). In addition, the authors recom-
end that PMAs work toward complete freedom from
ndustry support with regard to operational support, fund-
ng of society meetings (with the exception of exhibits and
dvertising), and funding of research and education. Lastly,
hey suggest that PMA officers and leadership should be
ree of all COIs during their time in office.17 Industry
upport of societies has been important in aiding continu-
ng educational venues, scholarship and travel grants, re-
earch funding, and professional development. Societies
ave also depended upon this support to bridge the gap
etween operational expenses and membership dues and
ther donations. With abrupt restrictions, many PMAs may
ave moderate to severe financial strain. Thus, it is incum-
ent upon leadership and membership to challenge them-
elves to restructure so that activities which support their
ission are continued and integrity and public trust main-
ained.
Finally, many AMCs have developed their own policies
round the physician–industry relationship; most recent to
ublish such a comprehensive set of guidelines was Emory
niversity in June 2009. In 2006, Coleman et al published
he guidelines used by the Yale Medical Group governing
heir interactions with industry.18 Interestingly, while the
ext of the article was relatively militant compared with
ther organizations such as the AAOS, the actual guide-ines were quite similar, and, while more specific than the
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lined above, around issues such as meals, COI disclosure,
free medication samples, speakers bureaus, CME events,
and the like.
As restrictions on industry funding of graduate and
postgraduate educational activities increase, there is great
concern over the impact on our ability to properly educate
our medical students, trainees, and vascular practitioners
effectively. Traditionally, many of these efforts have been
heavily supported by industry monies. There has been no
analysis to date of the potential negative effect of tightening
restrictions around these missions.
INDUSTRY’S POINT OF VIEW
While the physician’s interaction with industry, in gen-
eral, involves pharmaceuticals or medical devices (technolo-
gies), the surgeon’s interactions are more often concentrated
in the technology arena. Like physician organizations, the
recent intense scrutiny of physician/corporate interactions has
led industry to establish written codes of interaction or eth-
ics.19,20 These guidelines were developed by AdvaMed, the
trade association representing medical device manufactur-
ers. Although the standards are currently voluntary, mem-
ber companies have adopted the new standards. Whether
pharmaceutical or device company, those involved in for-
mulating the codes recognize the benefits of a robust
physician/corporate interaction, and in fact the guidelines
written by industry quite closely resemble those written by
physicians. In essence, the benefits inherent to such inter-
actions include the ability to provide a proper disclosure of
a product’s risk/benefit ratio to the physician, to develop or
improve on innovative products, to encourage research and
education, and to provide charitable contributions. The
risk is an inappropriate influence of physician use of a
product based on other than optimal patient care.19,20 The
goal of a written code of interaction (ethics) is to acknowl-
edge the fact that industry does understand that the first
duty of a physician is to act in the best interest of his/her
patients, to formulate guidelines to meet this goal, and to
establish a compliance program which ensures that these
guidelines are followed.
The basis of code development was to ensure that
collaborations meet high ethical standards in compliance
with current laws, regulations, and government guidance,
and with appropriate transparency.19,20 The specific areas
of concern written into both the pharmaceutical and med-
ical technology codes are quite similar. To avoid even the
appearance of impropriety, a company will provide no gift,
entertainment, or recreational item, irrespective of the cost,
to a nonemployee health care provider. Educational items
such as anatomical models, textbooks, or demonstration
products of modest value and devoid of value outside of the
health care arena (eg, CD, DVD, etc, not allowed) are
appropriate if the company provides documentation and
disclosure of the educational need and/or a no charge
status. Likewise, evaluation products provided at no cost to
allow a health care provider to assess the use and function-
ality of a product are allowed as long as the number and/or buration of the agreement are set in advance, in writing,
nd with no business productivity stipulations. During
ducational or business functions to disseminate informa-
ion or to discuss development or improvement of a prod-
ct/device, a modest meal can be provided, but only to
ona fide health care providers. Only expenses to a venue
onducive to a productive educational, research, or appro-
riate business endeavor (eg, hotels or commercially avail-
ble meeting facilities) of the bona fide health care provider
egitimately involved with that event can be covered; no
ther individual’s expenses can be covered (eg, significant
ther, etc). Such events may be for company-conducted
roduct training and education, especially in the case of
edical devices where such training is mandated by regu-
atory agencies. Health economics data, including insur-
nce coverage data, prescriber data, or reimbursement in-
ormation can be provided to the health care provider to
llow better access of care for their patients; however, a
ompany cannot provide any subsidized or free services that
ould eliminate an overhead or other expense of the pro-
ider. Charitable donations should not be given to individ-
als but rather to bona fide charitable organizations en-
aged in genuine and documented charitable efforts.
In a more global sense, support for CME and third
arty educational conferences is considered in some detail.
uch activities should not be directed or decided by the
ales or marketing departments, since such could easily be
isinterpreted as undue inducement to influence patient
are. Financial support should not be provided directly to
ealth care providers but rather to the third party educa-
ional provider (CME, regional or national associations,
tc.). The third party organizers must have full responsibil-
ty and control over the selection of content, faculty, edu-
ational materials, and venue with no advice or guidance by
he company. If support is provided as a grant to a training
nstitution or conference sponsor to allow attendance by
rainees, selection of the attendees is at the sole discretion
f the training program or conference sponsor. Educational
rants to support the training of medical students, resi-
ents, or fellows involved in an accredited training program
s appropriate, but the training facility has sole discretion
or every aspect of training. The concept is a separation of a
ompany’s general educational funding from a control of
ontent and personnel aimed at business advantage.
One of the most crucial issues is the health care pro-
ider as consultant to industry, so needed to allow innova-
ive product development and improvement but prone to
ndustrial influence in so many ways. Industry’s answer to
his challenge is transparency, fair market value, and the
efinition of expertise. Consulting agreements should be in
riting, describing the services to be provided; if it is a
esearch endeavor, there should be a written protocol. The
egitimacy of need should be documented. The qualifica-
ions and expertise of the consultant should be specifically
efined for the project being considered, and the consul-
ant should meet or exceed these requirements. Compen-
ation should be consistent with fair market value and not
ased on any marketing stipulations. The company sales
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include a particular health care provider. The company
should keep records documenting the efforts of the consul-
tant and how the company appropriately used the services
provided. Similar conditions should be set on speaker pro-
grams as to qualifications, expectations, and fair market
value for work preformed. The payment of royalties should
meet contractual standards. In no case should royalties be
conditioned on the purchase of product or on a require-
ment to market the product upon commercialization. In
some cases, research grants that provide valuable scientific
and clinical information by independent medical research
facilities can be supported. Such activities should have a
well-defined research protocol, objectives, and milestones
not linked directly or indirectly to the purchase of company
products. No matter the capacity a consultant serves within
a company, it is imperative that full disclosure of the ar-
rangement be provided when a consultant plays a separate
role for another entity (eg, committee member setting
formulary or devices for the operating room, clinical guide-
lines, etc).
But having a written code of conduct does not ensure
that the code is being implemented; a proper compliance
program must also be operative. Companies agreeing to
adopt the code are encouraged to submit an annual certi-
fication signed by the Chief Executive Officer and Chief
Compliance Officer to AdvaMed19 or Pharmaceutical Re-
search and Manufacturers of America20 stating that they
have adopted the code and have established a proper compli-
ance program. Web site acknowledgment of a company’s
participation will be available for public viewing, with the
contact information for the company’s Compliance Depart-
ment or an anonymous hotline to allow complaints of viola-
tions to be reported. The elements of an effective compliance
program have been published in several venues.19 The indi-
vidual compliance program, public notification, and an ave-
nue to report violation complaints provide a check on the
practical implementation of the code.
SUMMARY AND CONCLUSIONS
For better or worse, relationships between physicians
and industry are in a state of transition. The guidelines set
forth in this document reflect the current understanding of
what is appropriate with regard to interactions between phy-
sicians and industry, recognizing that these may not be the
guidelines we use 10 years hence. However, they serve as a
relevant set of standards reflective of current thinking and
policy making around these issues. They reflect, in addition,
the belief that there is much to be gained by a continued
collaboration with industry partners, and that those benefits
are best realized by creating an environment free of commer-
cial influence over research, education, and training.
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